The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Developments in the FL treatment landscape
Ryan Lynch, MD, Seattle Cancer Care Alliance, University of Washington, Seattle, WA, provides an overview of promising therapies for follicular lymphoma (FL). Whilst chemoimmunotherapy remains the standard of care for frontline treatment-naïve patients, patients who have relapsed/refractory FL can receive a wide range of therapies including lenalidomide, rituximab, PI3K inhibitors, EZH2 inhibitors, and chimeric antigen receptor (CAR) T-cell therapy. Dr Lynch additionally highlights the development of bispecific antibodies and the importance of choosing the right therapy based on patient characteristics and their wishes. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
